Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
Sara Cherri1, Laura Melocchi2, Laura Gandolfi2
1Department of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy.
Abstract:
In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as "untargetable"; today, we see the birth of new molecules that target one of the variants of the KRAS mutation, KRAS G12C, having a significant impact on the therapeutic options for other malignancies, such as metastatic lung cancer. This fundamental step forward has stimulated scientific research on other potential targets of KRAS, both indirect and direct, and combination treatments aiming to overcome the mechanisms of resistance to these drugs that decrease in efficacy in colorectal cancer. What was once a negative predictive marker of response to anti-EGFR drugs today has become a potential target for targeted treatments. In turn, the prognostic role of the mutation has become extremely interesting, making it a potentially useful element in therapeutic decision-making, not only regarding oncological treatments but also in a more complex and complete manner within a global vision of the patient, involving other figures on the multidisciplinary team, such as surgeons, radiotherapists, and interventional radiologists.
Insights
Precision medicine is advancing colorectal cancer treatment with targeted therapies for KRAS mutations, like KRAS G12C. Research is exploring new KRAS-targeting drugs and combinations to overcome resistance and improve patient outcomes.
Area of Science:
- Oncology
- Precision Medicine
- Molecular Oncology
Background:
- The KRAS mutation was historically considered untargetable in cancer treatment.
- Recent advancements have led to targeted therapies for specific KRAS variants, such as KRAS G12C, impacting treatment for metastatic lung cancer.
- This progress has spurred research into KRAS as a therapeutic target in other cancers, including colorectal cancer.
Purpose of the Study:
- To review the evolving role of KRAS mutations in colorectal cancer.
- To discuss the development of targeted therapies for KRAS mutations, particularly KRAS G12C.
- To explore strategies for overcoming resistance to KRAS-targeted therapies and combination treatments.
Main Methods:
- Literature review of precision medicine in colorectal cancer.
- Analysis of emerging targeted therapies for KRAS mutations.
- Examination of resistance mechanisms and combination treatment strategies.
Main Results:
- KRAS G12C-targeted therapies show promise, influencing treatment paradigms beyond lung cancer.
- The KRAS mutation is shifting from a negative predictive marker for anti-EGFR drugs to a potential therapeutic target.
- The prognostic significance of KRAS mutations is increasingly recognized, aiding therapeutic decision-making.
Conclusions:
- Targeted therapies for KRAS mutations represent a significant advancement in precision oncology for colorectal cancer.
- Further research into direct and indirect KRAS targeting, alongside combination therapies, is crucial for overcoming treatment resistance.
- The prognostic and predictive value of KRAS mutations necessitates a multidisciplinary approach to patient management.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers